Cullinan Therapeutics Inc (NASDAQ: CGEM) on Tuesday, soared 5.33% from the previous trading day, before settling in for the closing price of $8.06. Within the past 52 weeks, CGEM’s price has moved between $5.68 and $17.50.
During the last 5-year period, the sales drop of Healthcare Sector giant was -45.66%. The company achieved an average annual earnings per share of -35.12%. With a float of $36.84 million, this company’s outstanding shares have now reached $59.07 million.
Cullinan Therapeutics Inc (CGEM) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Cullinan Therapeutics Inc is 37.64%, while institutional ownership is 78.28%. The most recent insider transaction that took place on Oct 16 ’25, was worth 1,328,250. In this transaction 10% Owner of this company bought 150,000 shares at a rate of $8.86, taking the stock ownership to the 8,765,616 shares. Before that another transaction happened on Oct 15 ’25, when Company’s 10% Owner bought 51,500 for $7.94, making the entire transaction worth $409,049. This insider now owns 8,615,616 shares in total.
Cullinan Therapeutics Inc (CGEM) Earnings and Forecasts
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.69 earnings per share (EPS) for the period topping the consensus outlook (set at -0.77) by 0.08. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.91 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -35.12% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -4.59% during the next five years compared to -45.66% drop over the previous five years of trading.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Trading Performance Indicators
Cullinan Therapeutics Inc (CGEM) is currently performing well based on its current performance indicators. A quick ratio of 9.83 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.52, a number that is poised to hit -0.95 in the next quarter and is forecasted to reach -3.58 in one year’s time.
Technical Analysis of Cullinan Therapeutics Inc (CGEM)
Looking closely at Cullinan Therapeutics Inc (NASDAQ: CGEM), its last 5-days average volume was 0.83 million, which is a jump from its year-to-date volume of 0.55 million. As of the previous 9 days, the stock’s Stochastic %D was 36.69%.
During the past 100 days, Cullinan Therapeutics Inc’s (CGEM) raw stochastic average was set at 78.06%, which indicates a significant increase from 72.76% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.66 in the past 14 days, which was higher than the 0.43 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.07, while its 200-day Moving Average is $8.10. However, in the short run, Cullinan Therapeutics Inc’s stock first resistance to watch stands at $8.74. Second resistance stands at $9.00. The third major resistance level sits at $9.44. If the price goes on to break the first support level at $8.04, it is likely to go to the next support level at $7.60. Should the price break the second support level, the third support level stands at $7.34.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Key Stats
Market capitalization of the company is 501.54 million based on 59,074K outstanding shares. Right now, sales total 0 K and income totals -167,380 K. The company made 0 K in profit during its latest quarter, and -70,060 K in sales during its previous quarter.
